BlinkLab Granted Foundational U.S. Patent Covering Remote Neurobehavioural Testing Platform

Highlights:

• U.S. patent granted: United States Patent and Trademark Office grants patent protecting BlinkLab’s core remote neurobehavioral assessment technology, with exclusivity extending to 2041.
• ‍Strengthening of BlinkLab's intellectual property portfolio: Provides long-term protection for core technology underpinning BlinkLab's digital biomarker platform and supports future clinical, regulatory and commercial activities in key healthcare markets.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), a developer of AI-powered, smartphone-based neurobehavioural assessment technology, is pleased to announce that a keypatent underpinning its digital neurobehavioral assessment platform has been granted by the UnitedStates Patent and Trademark Office (USPTO).

The patent, titled "System and Method for Remote Neurobehavioral Testing", was granted as U.S.Patent No. 12,653,444 B2. The patent is expected to remain in force until November 2041, subject to the payment of maintenance fees and any applicable patent term adjustments. The patentapplication was filed by The Trustees of Princeton University on 10 November 2021. The patented technology was invented by Princeton University neuroscientists and BlinkLab co-founders, DrHenk-Jan Boele and Prof. Samuel S.-H. Wang.

BlinkLab holds an exclusive worldwide licence to the patented technology from Princeton University.The patent covers systems and methods for remote neurobehavioral assessment using audiovisualstimuli, including conditioned eyeblink responses and prepulse inhibition. These techniques form afundamental component of BlinkLab's proprietary digital biomarker platform and have beenincorporated into the Company's smartphone-based assessments for autism spectrum disorder andother neurodevelopmental conditions.

The grant provides intellectual property protection in the United States, the world's largest healthcaremarket, and further strengthens BlinkLab's growing portfolio of licensed and proprietary intellectualproperty.

BlinkLab Chief Executive Officer and Managing Director, Dr Henk-Jan Boele, commented:

‍"The grant of this U.S. patent of our invention is an important step for BlinkLab as we continuebuilding a scalable platform for objective neurological assessment. It protects core technology thatenables us to measure neurobehavioral responses remotely using everyday consumer devices such as smartphones. That capability sits at the heart of our mission to make neurological testing moreaccessible, affordable and available to people regardless of where they live. As we advance ourautism diagnostic programs and explore applications in other neurological and neurodevelopmental conditions, a strong intellectual property portfolio is an important part of creating long-term value.The U.S. is the world's largest healthcare market, and securing protection for this technologysupports our future clinical, regulatory and commercial plans."

The patent grant further enhances the Company's ability to develop and commercialise objective digital biomarkers for neurological and neurodevelopmental disorders. BlinkLab continues to expand its intellectual property portfolio through a combination of licensed patents, internally developed technology and ongoing research collaborations.

This announcement has been authorised for release by the Managing Director of BlinkLab Limited.